Best of the brokers for 29 August 2013

Numis keeps its “buy” rating and target price of 1,505p following interim figures at the support services group that were slightly ahead of expectations. The broker expects Bunzl to generate organic growth of between two and four per cent, or eight per cent including acquisitions.

Davy maintains its “outperform” rating on the miner and raises its target from 190p to 210p, pointing out that even with recent gains the shares are 66 per cent below their 52-week high. Davy says the firm is the cheapest gold miner that it covers.

Shore Capital retains a “buy” recommendation on the pharma group, noting big potential from the firm’s diversification efforts. The broker also likes Hikma’s expertise in the Middle Eastern markets, and sees a chance of management selling off the oral generics business.